Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19
No abstract present.
Main Authors: | Liudmila Buryachkovskaya, Nikita Lomakin, Arthur Melkumyants, Julia Docenko, Victor Serebruany |
---|---|
Format: | Article |
Language: | English |
Published: |
IMR (Innovative Medical Research) Press Limited
2021-09-01
|
Series: | Reviews in Cardiovascular Medicine |
Online Access: | https://rcm.imrpress.com/fileup/2153-8174/PDF/1632453053480-331266834.pdf |
Similar Items
-
Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
by: Nikita Lomakin, et al.
Published: (2019-12-01) -
Experience of olokizumab use in COVID-19 patients
by: V. N. Antonov, et al.
Published: (2020-12-01) -
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment
by: Irina V. Bure, et al.
Published: (2020-10-01) -
Nano-mechanical measurements of human erythrocytes, leukocytes, and platelets with atomic force microscopy
by: Chun-Ting Chiang, et al.
Published: (2010) -
The diagnostic value of platelet distribution width in patients with mild COVID-19
by: Fan, Z., et al.
Published: (2021)